Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (101-110 of 858) with videos related to

Pageof 86
Sort By:
Expert Opinion on Investigational Drugs|March 1, 2006
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factorsEli V Gelfand, Christopher P Cannon
Nature Clinical Practice. Cardiovascular Medicine|July 29, 2006
Update on lipid-lowering therapy and LDL-cholesterol targetsStephen D Wiviott, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Brigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarctionDavid A Morrow, Christopher P Cannon
Science (New York, N.Y.)|June 16, 2012
Physiology. COX-2 inhibitors and cardiovascular riskChristopher P Cannon, Paul J Cannon
Expert Opinion on Pharmacotherapy|June 15, 2005
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trialsKausik K Ray, Christopher P Cannon
Journal of the American College of Cardiology|October 18, 2005
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromesKausik K Ray, Christopher P Cannon
Journal of the American College of Cardiology|June 1, 2002
Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarctionChristopher P Cannon, Donald S Baim
European Heart Journal|May 15, 2015
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureYuichi J Shimada, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrelDalton S McLean, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) ProgramChristopher P Cannon, Joseph P Ornato
Pageof 86

Showing results (101-110 of 858) with videos related to

Sort By:
Pageof 86
Expert Opinion on Investigational Drugs|March 1, 2006
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factorsEli V Gelfand, Christopher P Cannon
Nature Clinical Practice. Cardiovascular Medicine|July 29, 2006
Update on lipid-lowering therapy and LDL-cholesterol targetsStephen D Wiviott, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
Brigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarctionDavid A Morrow, Christopher P Cannon
Science (New York, N.Y.)|June 16, 2012
Physiology. COX-2 inhibitors and cardiovascular riskChristopher P Cannon, Paul J Cannon
Expert Opinion on Pharmacotherapy|June 15, 2005
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trialsKausik K Ray, Christopher P Cannon
Journal of the American College of Cardiology|October 18, 2005
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromesKausik K Ray, Christopher P Cannon
Journal of the American College of Cardiology|June 1, 2002
Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarctionChristopher P Cannon, Donald S Baim
European Heart Journal|May 15, 2015
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureYuichi J Shimada, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrelDalton S McLean, Christopher P Cannon
Critical Pathways in Cardiology|March 15, 2008
How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) ProgramChristopher P Cannon, Joseph P Ornato
Pageof 86